U.S. Residential REITs Stock News

Peloton Interactive and the Formula 1 Las Vegas Grand Prix recently announced a collaboration to deliver exclusive fitness classes and experiences during the Grand Prix weekend, including onsite and virtual programming such as trackside workouts and scenic rides around the Las Vegas Strip Circuit. This partnership not only aligns Peloton with a global sports event but also extends the reach of its new Cross Training Series and leverages high-impact media exposure in a location known for its...

Dime Community Bancshares (DCOM) recently filed a universal shelf registration, which allows it to issue debt, equity, and other financial instruments. This move could set the stage for future financing opportunities and may influence how investors view the stock. See our latest analysis for Dime Community Bancshares. Over the past year, Dime Community Bancshares’ share price has trended lower, down 10.5% year-to-date and delivering a -16.5% total shareholder return. This comes despite the...

UroGen Pharma (URGN) has caught the attention of investors recently, with shares showing significant momentum over the past month. The company’s stock price has surged 37%, far outpacing broader industry trends and prompting fresh interest in its underlying story. See our latest analysis for UroGen Pharma. Zooming out, UroGen Pharma’s 37% share price rise over the past month has pulled it well ahead of the sector, building on a stellar year-to-date share price return of 122%. That momentum is...

Acadian Asset Management (NYSE:AAMI) just released its third quarter earnings, revealing strong revenue growth for both the quarter and year-to-date periods. However, despite higher revenues, quarterly net income and earnings per share ticked down slightly. See our latest analysis for Acadian Asset Management. Strong revenue growth has certainly put Acadian Asset Management on investors’ radar, but the market’s response has reflected both optimism and caution; while the stock has soared with...

Praxis Precision Medicines recently announced it has reached alignment with the FDA on using interim results from the EMBOLD study as a potential basis for early NDA submission for relutrigine in rare pediatric epilepsies, pending positive data in late 2025. This regulatory agreement marks an important step toward accelerating access to a potential first approved treatment for ultra-rare, life-threatening epileptic encephalopathies that currently have no FDA-approved options. We'll explore...

On November 6, 2025, Bread Financial Holdings closed a US$500 million offering of 6.750% Senior Notes due 2031, supported by guarantees from its key domestic subsidiaries and structured with multiple redemption options and terms balancing creditor and company interests. This move reflects Bread Financial’s focus on actively managing its capital structure and funding flexibility to support future growth and operational needs. We’ll examine how this expanded funding base could reinforce Bread...

CG Oncology (CGON) shares have been capturing attention lately, particularly given the swings seen over the past month. Investors seem curious about how these changes could reshape the company’s near-term prospects in the biotech sector. See our latest analysis for CG Oncology. After a strong 90-day share price return of 59.57% and a year-to-date climb of 41.56%, CG Oncology’s recent moves suggest that investor momentum is gathering pace. The 1-year total shareholder return of 24.67%...

DENTSPLY SIRONA reported a US$263 million noncash impairment charge related to goodwill and intangible assets for the third quarter of 2025, revised its full-year sales guidance downward, and announced the departure of its Chief Financial Officer. The impairment was primarily attributed to tariffs and reduced projected equipment, implant, and prosthetic volumes in the U.S., signaling potential challenges in some of the company’s core markets. We’ll examine how the impairment charge and...

F&G Annuities & Life announced a 14% increase in its quarterly common dividend to US$0.25 per share, alongside reporting robust third-quarter earnings with revenue reaching US$1.69 billion and net income of US$118 million, a turnaround from a net loss a year ago. This combination of a higher dividend and improved profitability highlights management's confidence in the company's cash flow and ongoing business momentum. We'll explore how the increased dividend signals sustained earnings...

Bumble Inc. recently reported third-quarter 2025 results showing improved profitability, despite sales falling to US$246.16 million from US$273.61 million in the prior year, and provided fourth-quarter revenue guidance in the US$216 million to US$224 million range. An additional shelf registration for US$127.2 million in Class A Common Stock was filed, connected to an employee stock ownership plan offering, underscoring Bumble's focus on employee incentives. We’ll assess how Bumble’s return...

Wondering if Photronics is underestimated or overpriced right now? You are not alone; many investors are taking a closer look at where true value might lie in this stock. Despite a dip of 2.7% over the past week and a 10.1% slide in the last month, Photronics still boasts an impressive 90.3% return over the last five years, which may hint at strong long-term potential. Recent news around advancements in semiconductor manufacturing processes and broader industry consolidation is sparking...

LegalZoom.com, Inc. recently raised its full-year 2025 revenue guidance to a range of US$748 million to US$752 million and reported third-quarter sales of US$190.16 million, alongside an update on its ongoing share repurchase program. While the company saw robust sales growth, its net income declined year-over-year, highlighting both current operational momentum and ongoing profitability challenges. We'll explore how LegalZoom's upgraded revenue guidance shapes the company's future outlook...

Earlier this month, Viridian Therapeutics announced the successful submission of a Biologics License Application (BLA) to the U.S. FDA for veligrotug, its investigational monoclonal antibody for thyroid eye disease, backed by data from two pivotal phase 3 trials. This milestone marks a significant regulatory step with the potential to offer a new therapy option for patients affected by thyroid eye disease, supported by evidence of efficacy and safety. We’ll explore how the BLA submission,...

Rubrik recently announced a strategic collaboration agreement with Amazon Web Services to enhance cybersecurity and advance secure AI adoption for organizations operating in cloud environments. This partnership introduces Rubrik’s Preemptive Recovery Engine to AWS customers, enabling proactive cyber resilience and unified recovery solutions against sophisticated threats. We'll explore how Rubrik's integration of preemptive data recovery with AWS could strengthen its position in the rapidly...

Adobe (ADBE) shared fresh updates this week, highlighting a substantial jump in online consumer spending along with a growing preference for mobile-first shopping. The company also expanded its Adobe Express partnership into India, unlocking access to millions of new creators. See our latest analysis for Adobe. Adobe shares have been on a choppy ride lately, with enthusiasm around innovation and new international partnerships offset by some persistent concerns. The stock's total shareholder...

Global-E Online (GLBE) has caught investors’ attention recently as its stock shifted direction following a few weeks of ups and downs. The company’s performance raises interesting questions for those weighing its potential after past volatility. See our latest analysis for Global-E Online. After a bumpy ride in the first half of the year, Global-E Online's share price has rebounded with a 15.2% gain over the past 90 days, suggesting some renewed optimism despite a year-to-date share price...

Zenas BioPharma (ZBIO) is in the spotlight after announcing strong Phase 2 results for obexelimab in relapsing multiple sclerosis, the launch of key Phase 3 trials, and a major funding deal with Royalty Pharma. See our latest analysis for Zenas BioPharma. Zenas BioPharma's impressive 90-day share price return of 108.09% and an exceptional year-to-date gain of 288.46% point to surging investor optimism, propelled by breakthrough clinical results and major funding milestones. Short-term...

Banc of California (BANC) shares have edged higher lately, with the stock up about 12% year to date and returning roughly 10% over the past three months. Investors seem to be considering the company’s growth story as markets assess recent performance. See our latest analysis for Banc of California. Banc of California’s latest share price return of nearly 12% this year stands out, with the momentum picking up pace over the past quarter. The total shareholder return over the last twelve months...

Earlier this month, McEwen Inc. reported a consolidated third-quarter production of 29,662 gold equivalent ounces, down from last year, and issued revised 2025 production guidance of 112,000–123,000 GEOs, narrowing its prior range. Despite operational headwinds and lower production figures, McEwen's net loss significantly narrowed for both the quarter and nine-month periods, reflecting tighter cost controls and improved financial resilience. We'll now explore how McEwen's reduced production...

Wondering if First Solar’s recent performance means the stock is a bargain or just riding a wave? You’re in the right place for a closer look at what the numbers (and a bit of context) might really be telling us. First Solar’s stock has made some serious moves lately, climbing 35.7% year-to-date and 32.9% over the past year. However, it dipped 5.4% in the past week, which may signal that volatility could be as much an opportunity as a warning sign. This past month, First Solar’s price shifts...

California Water Service Group (CWT) recently drew attention after a Baird analyst updated their outlook. This update followed the release of the company’s third-quarter results and management’s comments on pending regulatory decisions and infrastructure plans. See our latest analysis for California Water Service Group. California Water Service Group’s share price has hovered near the flatline in recent months, but momentum has not yet shifted in a meaningful way. Over the past year, the...

In the past week, Bristol Myers Squibb and Johnson & Johnson announced the early discontinuation of their Phase 3 Librexia ACS trial for milvexian in acute coronary syndrome patients after an interim analysis indicated the trial would not achieve its primary efficacy goal, although no new safety issues were identified. This outcome has positioned increased attention on the success of Bristol Myers Squibb’s other late-stage cardiovascular programs and the company’s ability to manage pipeline...

The Cincinnati Bengals announced a partnership with Shift4 Payments to upgrade and streamline all payment transactions throughout Paycor Stadium, leveraging Shift4’s commerce platform for food and beverage concessions. This move highlights Shift4’s expanding presence in the sports and entertainment sector, aiming to deliver faster and more secure payment experiences for fans. We’ll explore how the Bengals partnership may influence Shift4’s broader investment narrative and potential sector...

Curious whether Bitmine Immersion Technologies is actually worth its eye-catching stock price? You're not alone, and there's a lot more to the value story than meets the eye. The stock has rocketed 473.3% over the past year, even after a recent dip of 36.1% in the last month. This shows just how quickly sentiment and growth expectations can shift. Bitmine Immersion Technologies has attracted attention amid recent industry chatter about high-performance computing demand and renewed discussion...